Genmab — Maj 2021

[Stroka]

Details of each transaction are included as an appendix to this announcement.

Following these transactions, Genmab holds 240,306 shares as treasury shares, corresponding to 0.37% of the total share capital and voting rights.

[Helge_LarsenPI-redaktør]

Sorry Stroka at jeg blandede mig. Jeg troede at du havde glemt noget af meddelelsen.

[Stroka]

Det er ok..Jeg fumlede med mobilen. Iøvrigt er det en fin kursudvikling på en Q&A dag.

[deleted-user]

@stockbull - tillykke med salget i morges. Pas nu på du ikke presser prisen for meget, når du genkøber til eftermiddag

[GeorgeBest]

** Genmab GMAB.CO shares are up 3.5% after J.P. Morgan raises its share price target for the Danish biopharmaceutical company to 2,500 Danish crowns from 2,350 crowns
** The brokerage sees several important updates from the company in the second half of the year, particularly on its GEN1046 and epcoritamab treatments
** It moves forward its expected launches for both treatments to 2024, from 2025 previously, based on comments during the company's Q1 results call

[GeorgeBest]

** JPM forecasts 2021 revenues of 7.50 billion crowns ($1.23 billion) and operating income of 1.86 billion crowns, both towards the upper end of the company's guidance range
** It reiterates an "overweight" rating on the stock
** Out of 27 analysts that cover Genmab, 18 rate the stock "strong buy" or "buy", six rate it "hold" and three rate it "strong sell" or "sell"

[GeorgeBest]

Nordea's kommenterer ligeledes i dag. Ser signifikant nyhedsflow fra pipeline de naeste 6 maaneder

[kkjoel]

GB, tak.

[kkjoel]

Helge, har lagt nogle spørgsmål..

[Helge_LarsenPI-redaktør]

Tak kkjoel. Jeg håber at få tid til dem alle.

[E_L]

thks GB. Did JPM not hear Jan say on Epco 'potential product filing and approval within 2022.'...? gives a bit of room for another upgrade

[Helge_LarsenPI-redaktør]

Q&A starter kl. 15.

[GeorgeBest]

Agree E L

[kkjoel]

He said to Michael Schmidt, Guggenheim, at 2021 Q1 cc: "The expansion cohorts will be over 100 patients for each of the expansion cohorts."... "So hopefully, updates also during this year on how that progresses. And we think that, each of these could potentially be used for potential accelerated filing, if the data would allow that. And we certainly, will have interactions with the regulatory authorities on that."

[kkjoel]

"
That we can potentially file in 2022 for an accelerated pathway for at least one of these expansion cohorts perhaps more depending on how recruitment will go in the coming time."

[kkjoel]

Tak, Helge. Specielt nr 2 (13:52) kunne være sjovt at få en bare lillebitte reel kommatar til (Selvom vi godt ved han nok ikke siger en dyt)

[kkjoel]

Ja, Pens - alle derude ved jo at større spørgsmål altid belyses - nogen gange ligefrem afklares - på PI kvartals-Q&A

[kkjoel]

Meeeen - der var vist noget med et kæmpe efterslæb ift. NQ Biotech
fra i onsdags, ja?!

[kkjoel]

Jam sluttede af med: "..remain optimistic". Dejlig at høre.. from The Opti-Maestro himself

[kkjoel]

Og tak til dig, Helge - fint modereret